Database release

This release contains 993 approved relationships.

Added entries:

(FDA) EGFR p.L858R and exon 19 deletions and sensitivty to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of patients with non-small cell lung cancer.
(FDA) EGFR p.L858R and exon 19 deletions and sensitivty to osimertinib for the treatment of patients with non-small cell lung cancer.

Revised entries:

(FDA) RET somatic variants and sensitivity to selpercatinib for the treatment of patients with medullary thyroid cancer received an approval from the FDA, previously accelerated approval.
(FDA) The description of three records corresponding to FDA approved indications for osimertinib were edited for clarity.
(FDA) Six records for capivasertib in combination with fulvestrant incorrectly categorized fulvestrant as a targeted therapy. It has been updated to be a hormone therapy, and the therapy_type for each of these records has been updated to be “Combination therapy”.
(Clinical evidence) The PMID for Bostner et al. was incorrected listed as “7486065” instead of “17486065”. The evidence category was also changed from Clinical evidence to Clinical trial. Thank you, Cameron Grisdale!

Four records listed therapy type either as “Targeted therapy + Chemotherapy”, “Targeted therapy + Chemotherapy + Chemotherapy”, or “Chemotherapy + Targeted therapy + Chemotherapy” instead of “Combination therapy”. These records have been updated.